Zealand Pharma As Stock Fundamentals
| ZLDPF Stock | USD 99.52 4.53 4.35% |
Zealand Pharma AS fundamentals help investors to digest information that contributes to Zealand Pharma's financial success or failures. It also enables traders to predict the movement of Zealand Pink Sheet. The fundamental analysis module provides a way to measure Zealand Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zealand Pharma pink sheet.
Zealand |
Zealand Pharma AS Company Shares Owned By Insiders Analysis
Zealand Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Zealand Pharma Shares Owned By Insiders | 0.07 % |
Most of Zealand Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 0.07% of Zealand Pharma AS are shares owned by insiders. This is 99.54% lower than that of the Healthcare sector and 99.51% lower than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 99.31% higher than that of the company.
Zealand Pharma AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zealand Pharma's current stock value. Our valuation model uses many indicators to compare Zealand Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zealand Pharma competition to find correlations between indicators driving Zealand Pharma's intrinsic value. More Info.Zealand Pharma AS is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zealand Pharma's earnings, one of the primary drivers of an investment's value.Zealand Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zealand Pharma's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Zealand Pharma could also be used in its relative valuation, which is a method of valuing Zealand Pharma by comparing valuation metrics of similar companies.Zealand Pharma is currently under evaluation in shares owned by insiders category among its peers.
Zealand Fundamentals
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 4.03 X | |||
| Price To Book | 27.79 X | |||
| Price To Sales | 5.19 X | |||
| Revenue | 292.57 M | |||
| Gross Profit | 173.75 M | |||
| EBITDA | (982.6 M) | |||
| Net Income | (1.02 B) | |||
| Cash And Equivalents | 864.44 M | |||
| Cash Per Share | 18.68 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.96 % | |||
| Current Ratio | 3.83 X | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (3.26) X | |||
| Target Price | 22.4 | |||
| Number Of Employees | 203 | |||
| Beta | 0.95 | |||
| Market Capitalization | 1.57 B | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | (1.24 B) | |||
| Working Capital | 356 M | |||
| Current Asset | 408 M | |||
| Current Liabilities | 52 M | |||
| Z Score | 1.2 | |||
| Net Asset | 2.07 B |
About Zealand Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Zealand Pharma AS, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 237 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.